How many Europeans are affected by VKC?

Article

The prevalence of vernal keratoconjunctivitis (VKC) in Europe is 3.2 per 10000 inhabitants, according to a study published in the August 2008 issue of the British Journal of Ophthalmology.

The prevalence of vernal keratoconjunctivitis (VKC) in Europe is 3.2 per 10000 inhabitants, according to a study published in the August 2008 issue of the British Journal of Ophthalmology.

Dominique Brémond-Gignac of the Service d’Ophtalmologie, APHP, Hôpital Robert Debré, Paris, France and colleagues sent a survey to 3003 ophthalmologists across six countries with, cumulatively, 151.9 million inhabitants. The team analyzed the results to extrapolate data for number of VKC cases across the 15 European Union member states (2002). The survey response rate was 29.5% (n=886).

The team estimated 1.16–10.55 inhabitants per 10000 in Western European to be affected by VKC, with 0.30–2.26 per 10000 to be affected by VKC with corneal complications. The prevalence of VKC was found to be lower than expected in most countries questioned, although in Italy the range was 2.4–27.8/10000. However, the ranges for VKC prevalence were 0.7–8.4, 1.2–8.7, 0.6–4.6, 0.7–3.3 and 0.3–1.9 in Finland, Sweden, the Netherlands, France and Norway, respectively. The rate of VKC with corneal complications was 0.4–4.8, 0.3–2.4, 0.2–2.8, 0.2–1.6, 0.3–1.4 and 0.1–1.0 for each of these countries, respectively.

The team concluded that, based on the correlated and extrapolated data, it was most likely that VKC affects 3.2 of every 10000 people in Western Europe, and that the rate of corneal complications with the disease is 0.8 per 10000.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jay Chhablani, MD, shares late-breaking data from the ArMaDa trial, investigating gene therapy for Geographic Atrophy and dry age-related macular degeneration, at EURETINA
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
María Berrocal, MD, speaks about the Vit-Buckle Society symposium hosted at the 2025 European Society of Retina Specialists (EURETINA) annual meeting
© 2025 MJH Life Sciences

All rights reserved.